DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for hereditary hemochromatosis type 1 — screening already-approved drugs against its 5-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleHereditary hemochromatosis type 1 maps to a 5-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for hereditary hemochromatosis type 1 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
bone morphogenetic protein 2 (BMP2) — BMP2 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet ndgdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 2GOO · 2.2 Å · ligand 2-acetamido-2-deoxy-alpha-D-glucopyranose (NDG). Experimental structure, not a prediction.
What the evidence adds up to
In a large Italian family with hereditary iron overload indistinguishable from classic haemochromatosis, none of the 53 members studied carried the C282Y mutation in the HFE gene. Fifteen members had abnormal serum ferritin, transferrin saturation above 50 percent, or both; thirteen of those fifteen underwent iron-removal therapy. Five of the fifteen carried a different HFE mutation (H63D), but none were homozygous for it, and sequencing of the entire HFE gene in all family members found no other mutations. Microsatellite analysis showed no linkage of the iron-overload phenotype with the short arm of chromosome 6, where HFE sits. The authors concluded that hereditary haemochromatosis can occur in adults without pathogenic mutations in the HFE gene.
A 1998 review stated that early diagnosis and treatment of haemochromatosis gives an excellent long-term prognosis and that a diagnostic genetic test had improved the feasibility of preventing morbidity and mortality. A 2003 rebuttal noted a disagreement about penetrance: the authors of the rebuttal maintained that their study of Kaiser-Permanente patients showed lower penetrance than the figure argued by Ajioka and Kushner. The abstract does not give the actual penetrance numbers from either side.
A 2025 report on juvenile haemochromatosis described a patient with novel compound heterozygous mutations in the hemojuvelin gene. The authors suggested that long-term, strategic phlebotomy might offer a novel therapeutic strategy for severe juvenile haemochromatosis, challenging traditional treatment paradigms. No survival or response-rate data are given in that abstract.
What is still missing is a prospective trial that stratifies patients by genotype (HFE versus non-HFE, including hemojuvelin mutations) and measures clinical outcomes such as fibrosis progression, survival, and quality of life under standard phlebotomy versus any alternative regimen. The natural history and penetrance of non-HFE iron overload remain poorly quantified, and no randomised comparison of phlebotomy schedules exists for juvenile haemochromatosis. Funding for such a trial, and for systematic genotyping of iron-overload cohorts, is lacking.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
New England Journal of Medicine · 1999 · 274 citations · open access
Hereditary Hemochromatosis in Adults without Pathogenic Mutations in the Hemochromatosis Gene
AbstractBACKGROUND AND METHODS: Hereditary hemochromatosis in adults is usually characterized by mutations in the HFE gene on the short arm of chromosome 6. Most patients have a substitution of tyrosine for cysteine at position 282 (C282Y). We studied a large family from Italy that includes persons who have a hereditary iron-overload condition indistinguishable from hemochromatosis but without apparent pathogenic mutations in the HFE gene. We performed biochemical, histologic, and genetic studies of 53 living members of the family, including microsatellite analysis of chromosome 6 and direct sequencing of the HFE gene. RESULTS: Of the 53 family members, 15 had abnormal serum ferritin levels, values for transferrin saturation that were higher than 50 percent, or both. Thirteen of the 15 had elevated body iron levels, diagnosed on the basis of the clinical evaluation and liver biopsy, and underwent iron-removal therapy. The other two, both children, did not undergo liver biopsy or iron-removal therapy. None of the 15 members had the C282Y mutation of the HFE gene; 5 of the 15 (as well as 5 healthy relatives) had another mutation of this gene, a substitution of aspartate for histidine at position 63, but none were homozygous for it. No other mutations were found after sequencing of the entire HFE gene for all family members. Microsatellite analysis showed no linkage of the hemochromatosis phenotype with the short arm of chromosome 6, the site of the HFE gene. CONCLUSIONS: Hereditary hemochromatosis can occur in adults who do not have pathogenic mutations in the hemochromatosis gene.
Hemochromatosis: New Insights in Pathogenesis and Diagnosis Following the Discovery of the Gene
AbstractHemochromatosis is a common and often underdiagnosed disease. Early diagnosis and treatment results in an excellent long-term prognosis. The development of a diagnostic genetic test has improved the feasibility of the goal of prevention of morbidity and mortality from hemochromatosis.
AbstractDrs Richard S. Ajioka and James P. Kushner provide an able review of the studies that have led them to conclude that the penetrance of hereditary hemochromatosis is much higher than our study of Kaiser-Permanente patients has shown it to be. They suggest that the cause of the discrepancy is
World Journal of Clinical Cases · 2025 · 0 citations · open access
Reference diagnosis and treatment process of juvenile hemochromatosis patients
Abstract, published in a renowned medical journal, is an excellent example of meticulous clinical evaluation, comprehensive laboratory testing, advanced imaging, and genetic analysis. The authors identified novel compound heterozygous mutations in the hemojuvelin gene of a patient diagnosed with juvenile hemochromatosis. They suggested that long-term, strategic phlebotomy might offer a novel therapeutic strategy for severe juvenile hemochromatosis, challenging the traditional treatment paradigms.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
